CVRx replaces chief revenue officer amid sales shift

CVRx, Inc. reported that the employment of Chief Revenue Officer Robert John terminated effective immediately on August 10, 2026, under circumstances that entitle him to severance pay and benefits in line with his employment agreement.

Rhea-AI Filing Summary

CVRx, Inc. reported that the employment of Chief Revenue Officer Robert John terminated effective immediately on August 10, 2026, under circumstances that entitle him to severance pay and benefits in line with his employment agreement. The company also announced a sales leadership transition in which Paul Verrastro, a long-time CVRx executive with more than 30 years of medical device sales and marketing experience, has been appointed Interim Head of Sales effective immediately while a search for a permanent successor is conducted. Management stated that a revised commercial outlook and the need to improve commercial execution led to the change in sales leadership.

Positive

• None.

Negative

• CVRx’s Chief Revenue Officer departed effective August 10, 2026, with the change explicitly linked to a revised commercial outlook and the need to improve commercial execution, signaling potential challenges in the company’s current sales performance.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

CRO termination date: August 10, 2026 Press release date: August 11, 2026 Interim head experience: More than 30 years

3 metrics

CRO termination date August 10, 2026 Effective date of Robert John’s employment termination as Chief Revenue Officer

Press release date August 11, 2026 Date of the announced sales leadership transition press release

Interim head experience More than 30 years Medical device sales and marketing experience of Interim Head of Sales Paul Verrastro

Key Terms

Emerging growth company, neuromodulation, Breakthrough Device designation, cardiac resynchronization therapy (CRT), +1 more

5 terms

Emerging growth company regulatory

"Emerging growth company x"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

neuromodulation medical

"commercializing innovative neuromodulation solutions for patients with cardiovascular diseases"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

Breakthrough Device designation medical

"Barostim received the FDA Breakthrough Device designation"

A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.

cardiac resynchronization therapy (CRT) medical

"including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT)"

CE Mark approval regulatory

"holds CE Mark approval for heart failure and resistant hypertension"

CE mark approval is a declaration that a product meets European safety, health and performance requirements and may be placed on the market in the European Economic Area; for regulated items such as medical devices this follows required testing or a conformity assessment. Think of it as a passport or safety sticker that opens access to European customers; for investors it reduces regulatory roadblocks and can materially expand addressable market and revenue potential, though it is not a guarantee of commercial success.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did CVRX (CVRX) announce in this Form 8-K?

CVRx announced that Chief Revenue Officer Robert John’s employment terminated effective August 10, 2026. The company has begun a transition in sales leadership following his departure under severance-eligible circumstances defined in his employment agreement.

Who will lead sales at CVRX (CVRX) after the Chief Revenue Officer’s departure?

CVRx appointed Paul Verrastro as Interim Head of Sales effective immediately. He will oversee the sales organization while the company conducts a search for a permanent successor to the Chief Revenue Officer role.

Why did CVRX (CVRX) change its sales leadership team?

President and CEO Kevin Hykes stated that a revised commercial outlook and need to improve commercial execution led CVRx to change sales leadership, indicating the move is driven by current commercial performance considerations.

What experience does the new Interim Head of Sales at CVRX (CVRX) have?

Interim Head of Sales Paul Verrastro brings more than 30 years of medical device sales and marketing experience. He has been with CVRx for over five years and previously served as Chief Marketing and Strategy Officer and a senior advisor on commercial execution.

Does Robert John receive severance in connection with his departure from CVRX (CVRX)?

Yes. CVRx disclosed that Robert John’s employment terminated under circumstances entitling him to severance pay and benefits under his employment agreement, subject to the applicable conditions set forth in that agreement.

What product focus does CVRX (CVRX) highlight in connection with this leadership transition?

CVRx highlights Barostim, described as the first FDA-approved neuromodulation technology for improving heart failure symptoms. The device delivers electrical pulses to carotid baroreceptors to help restore autonomic balance in heart failure patients.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 07:09 AM Accepted by SEC EDGAR 08/11/2026 - 07:09 AM Learn about SEC filing dates

false 0001235912 0001235912 2026-08-10 2026-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 10, 2026

CVRx, Inc. 

(Exact name of registrant as specified in its charter)

Delaware		001-40545		41-1983744
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

9201 West Broadway Avenue, Suite 650 

Minneapolis, MN 55445 

(Address of principal executive offices) (Zip Code)

(763) 416-2840 

(Registrant’s telephone number, including area code)

N/A 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		CVRX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 10, 2026, the employment of Robert John, the Chief Revenue Officer of CVRx, Inc., terminated effective immediately, under circumstances entitling him to severance pay and benefits under his employment agreement, subject to the conditions therein.

A press release announcing the foregoing is attached as Exhibit 99.1 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release of CVRx, Inc., dated August 11, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CVRx, Inc.
Date: August 11, 2026	By:	/s/ Jared Oasheim
		Name: Jared Oasheim
		Its: Chief Financial Officer

Exhibit 99.1

CVRx Announces Sales Leadership Transition

Robert John to Depart as Chief Revenue Officer; Paul Verrastro Named Interim Head of Sales

MINNEAPOLIS, August 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that Robert John, Chief Revenue Officer, will depart the company, and that Paul Verrastro will assume the role of Interim Head of Sales, effective immediately.  In his new role, Mr. Verrastro will lead CVRx’s sales organization while the company conducts a search for a permanent successor.

Mr. Verrastro brings more than 30 years of medical device sales and marketing experience to the role. He has been with CVRx for over five years and recently moved into a new senior advisor role focused on commercial execution support. Prior to assuming this role, he was most recently Chief Marketing and Strategy Officer. Prior to joining CVRx, he held sales and marketing leadership positions at Guidant, Boston Scientific and Medtronic, much of that work focused on bringing novel therapies and technologies to market, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT).

“Our revised commercial outlook and need to improve commercial execution have led us to make a change in sales leadership,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “I have full confidence in Paul’s ability to lead our sales team while we search for a new leader. He knows our business, our customers and our commercial strategy, and is well respected by the sales force. This continuity will serve us well as we work through this transition.”

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie

ICR Healthcare

443-213-0501

ir@cvrx.com

Media Contact:

Emily Meyers

CVRx, Inc.

763-416-2853

emeyers@cvrx.com

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 6.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB